Enrollment concluded for study of cord blood stem cell product


Gamida Cell has that the company's joint venture with Teva Pharmaceutical Industries has completed enrollment of the last of 100 patients for their international, multi-center, pivotal registration, Phase III clinical trial of StemEx, the cell therapy product being developed as an alternative therapeutic treatment for people with leukemia or lymphoma who need a stem cell transplant but can not find a matched donor.

According to the press release, StemEx is "a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV administration along with the remaining, non-manipulated cells from the same unit."

The hope is that the companies can bring StemEx to market in 2013.

Source: BusinessWeek

LymphomaInfo Social